Clinical Trial Update: 89Zr-labeled Pembrolizumab in Patients With Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update investigating 89Zr-labeled pembrolizumab for imaging in patients with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Amsterdam UMC, location VUmc | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: UNKNOWN